Search results for "Biopterin"

showing 10 items of 25 documents

Identification of 5,6,7,8-tetrahydropterin and 5,6,7,8-tetrahydrobiopterin in Drosophila melanogaster.

1988

Summary Using reversed-phase high-performance liquid chromatography with electrochemical detection we have demonstrated the occurrence of 5,6,7,8-tetrahydropterin and 5,6,7,8-tetrahydrobiopterin in Drosophila melanogaster . The former is the first time that has been detected in vivo . The identification has been based on the retention times, hydrodinamic voltagrams and the differential concentration in three strains of Drosophila melanogaster . Compared to the wild type, the Punch 2 mutant has diminished levels of both pteridines, whereas Henna-recessive 3 lacks completely tetrahydropterin and has increased levels of tetrahydrobiopterin, as expected according to their biochemical lesions.

GeneticsbiologyMutantBiophysicsWild typeCell BiologyElectrochemical detectionTetrahydrobiopterinbiology.organism_classificationKidneyBiochemistryHigh-performance liquid chromatographyBiopterinPterinsRatsDrosophila melanogasterBiochemistryIn vivomedicineAnimalsDrosophila melanogasterMolecular BiologyChromatography High Pressure Liquidmedicine.drugBiochemical and biophysical research communications
researchProduct

Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets?

2013

International audience; Nitric oxide (• NO) is synthetized enzymatically from L-arginine (L-Arg) by three NO synthase isoforms, iNOS, eNOS and nNOS. The synthesis of NO is selectively inhibited by guanidino-substituted analogs of L-Arg or methylarginines such as asymmetric dimethylarginine (ADMA), which results from protein degradation in cells. Many disease states, including cardiovascular diseases and diabetes, are associated with increased plasma levels of ADMA. The N-terminal catalytic domain of these NOS isoforms binds the heme prosthetic group as well as the redox cofactor, tetrahydrobiopterin (BH 4) associated with a regulatory protein, calmodulin (CaM). The enzymatic activity of NOS…

NO inhibitorsfree radicals030204 cardiovascular system & hematologyProtein degradationPharmacologyNitric OxideNitric oxide03 medical and health scienceschemistry.chemical_compoundBH 40302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemcardiovascular diseaseEnosmedicineAnimalsHumansPharmacology (medical)Enzyme InhibitorsEndothelial dysfunctionReactive nitrogen species030304 developmental biologyPharmacologyNO synthases0303 health sciencesbiologyTetrahydrobiopterinbiology.organism_classificationmedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthADMANitric oxide synthaseOxidative StresschemistryBiochemistryCardiovascular Diseasesbiology.proteinNitric Oxide SynthaseAsymmetric dimethylargininemedicine.drugPharmacology & Therapeutics
researchProduct

Nitric Oxide Synthesis in Vascular Physiology and Pathophysiology

2015

Nitric oxide (NO) is produced by three NO synthase (NOS) isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). Under physiological conditions, vascular NO is produced by eNOS and nNOS, with both playing atheroprotective roles. Under pathological conditions, iNOS can be induced and eNOS may become uncoupled. iNOS produces a large amount of NO, induces vascular dysfunction, and promotes atherogenesis. Uncoupled eNOS generates superoxide instead of NO and contributes significantly to endothelial dysfunction and atherogenesis. Major mechanisms of eNOS uncoupling include depletion of tetrahydrobiopterin, an essential co-factor for the eNOS enzyme, and deficiency of L-a…

medicine.medical_specialtyNADPH oxidasebiologyChemistrySuperoxideNitric Oxide Synthase Type IIITetrahydrobiopterinmedicine.diseasebiology.organism_classificationEndothelial NOSNitric oxidechemistry.chemical_compoundEndocrinologyEnosInternal medicinemedicinebiology.proteinEndothelial dysfunctionmedicine.drug
researchProduct

eNOS Uncoupling in Cardiovascular Diseases - the Role of Oxidative Stress and Inflammation

2013

Many cardiovascular diseases and drug-induced complications are associated with - or even based on - an imbalance between the formation of reactive oxygen and nitrogen species (RONS) and antioxidant enzymes catalyzing the break-down of these harmful oxidants. According to the “kindling radical” hypothesis, the formation of RONS may trigger in certain conditions the activation of additional sources of RONS. According to recent reports, vascular dysfunction in general and cardiovascular complications such as hypertension, atherosclerosis and coronary artery diseases may be connected to inflammatory processes. The present review is focusing on the uncoupling of endothelial nitric oxide synthas…

medicine.medical_specialtyNitric Oxide Synthase Type IIIInflammationOxidative phosphorylationmedicine.disease_causechemistry.chemical_compoundEnosInternal medicineDrug DiscoverymedicineHumansEndothelial dysfunctionInflammationPharmacologybiologyTetrahydrobiopterinbiology.organism_classificationmedicine.diseaseReview articleOxidative StressEndocrinologychemistryCardiovascular Diseasesmedicine.symptomAsymmetric dimethylarginineOxidative stressmedicine.drugCurrent Pharmaceutical Design
researchProduct

Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis

2013

[Background]: Pulmonary hypertension in idiopathic pulmonary fibrosis (IPF) is indicative of a poor prognosis. Recent evidence suggests that tetrahydrobiopterin (BH4), the cofactor of nitric oxide synthase (NOS), is involved in pulmonary hypertension and that pulmonary artery endothelial-to-mesenchymal transition (EnMT) may contribute to pulmonary fibrosis. However, the role of BH4 in pulmonary remodelling secondary to pulmonary fibrosis is unknown. This study examined the BH4 system in plasma and pulmonary arteries from patients with IPF as well as the antiremodelling and antifibrotic effects of the BH4 precursor sepiapterin in rat bleomycin-induced pulmonary fibrosis and in vitro EnMT mod…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtySepiapterinPathologyNitric Oxide Synthase Type IIIHypertension PulmonaryPulmonary FibrosisNitric Oxide Synthase Type IIEnzyme-Linked Immunosorbent AssayPulmonary ArteryReal-Time Polymerase Chain ReactionEndothelial NOSchemistry.chemical_compoundIdiopathic pulmonary fibrosisInternal medicinemedicine.arteryPulmonary fibrosismedicineAnimalsHumansRats WistarGTP CyclohydrolaseSepiapterin reductaseChromatography High Pressure LiquidAgedbusiness.industryNitrotyrosineMiddle Agedmedicine.diseaseBiopterinImmunohistochemistryPulmonary hypertensionRatsAlcohol OxidoreductasesDisease Models AnimalEndocrinologychemistryPulmonary arteryTyrosineFemaleEndothelium Vascularbusiness
researchProduct

Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease.

2013

Nitric oxide (NO) produced by the endothelial NO synthase (eNOS) is an antihypertensive, antithrombotic and anti-atherosclerotic molecule. Hypercholesterolemia leads to a reduction in vascular NO bioavailability. This is attributed to a dysfunction of the eNOS enzyme and a reduced eNOS activity. NADPH oxidase-mediated oxidative stress leads to oxidation of tetrahydrobiopterin (BH4), the essential cofactor of eNOS. In BH4 deficiency, oxygen reduction uncouples from NO synthesis, thereby converting eNOS to a superoxide-producing enzyme. As a consequence of eNOS uncoupling, NO production is reduced and the pre-existing oxidative stress is enhanced, which contribute significantly to atherogenes…

Pharmacologymedicine.medical_specialtyAngiotensin II receptor type 1biologyNitric Oxide Synthase Type IIINitric Oxide Synthase Type IIITetrahydrobiopterinResveratrolbiology.organism_classificationmedicine.disease_causeNitric OxideNebivololNitric oxidechemistry.chemical_compoundEndocrinologychemistryEnosInternal medicineDrug DiscoverymedicineAnimalsHumansVascular DiseasesOxidative stressmedicine.drugCurrent opinion in pharmacology
researchProduct

Regulation of pteridine biosynthesis and aromatic amino acid hydroxylation in Drosophila melanogaster

1989

The relationship between high dietary levels of aromatic amino acid and regulation of pteridines in Drosophila eyes was examined by measuring changes in pool levels of six pterins in the wild type and mutants and amino acid pool levels in flies that carry mutations for pteridine biosynthesis. The effect upon relative viability and developmental times was also analyzed; relative viability was affected by L-phenylalanine, L-tryptophan, and L-tyrosine in decreasing order and the D-amino acids had little or no effect. The changes in concentration of biopterin, dihydrobiopterin, pterin, sepiapterin, drosopterins, and isoxanthopterin showed a characteristic pattern of increased and/or decreased a…

PhenylalanineBiopterinPhenylalanineBiologyHydroxylationBiochemistrychemistry.chemical_compoundDihydrobiopterinGeneticsmedicineAromatic amino acidsAnimalsAmino AcidsPterinMolecular BiologyEcology Evolution Behavior and Systematicschemistry.chemical_classificationPteridinesTryptophanGeneral MedicineTetrahydrobiopterinAmino acidDrosophila melanogasterchemistryBiochemistryMutationTyrosinePteridinemedicine.drug
researchProduct

Implication of eNOS Uncoupling in Cardiovascular Disease

2017

Under physiological conditions, nitric oxide (NO) is produced in the vasculature mainly by the endothelial nitric oxide synthase (eNOS). Endothelial NO relaxes blood vessels, inhibits platelet activity, and protects against atherosclerosis. Under pathological conditions such as hypertension, diabetes, and hypercholesterolemia, eNOS may become uncoupled. Uncoupled eNOS generates superoxide at the expense of NO and contributes substantially to oxidative stress and endothelial dysfunction. Major mechanisms of eNOS uncoupling include deficiency of the eNOS cofactor tetrahydrobiopterin, deficiency of the eNOS substrate L-arginine, and eNOS S-glutathionylation. Reversal of eNOS uncoupling may rep…

chemistry.chemical_classificationmedicine.medical_specialtyReactive oxygen speciesbiologybusiness.industrySuperoxideTetrahydrobiopterinbiology.organism_classificationmedicine.disease_causemedicine.diseaseNitric oxidechemistry.chemical_compoundEndocrinologychemistryEnosInternal medicinemedicinePlatelet activationEndothelial dysfunctionbusinessOxidative stressmedicine.drugReactive Oxygen Species
researchProduct

Nitric oxide synthases: regulation and function

2011

Nitric oxide (NO), the smallest signalling molecule known, is produced by three isoforms of NO synthase (NOS; EC 1.14.13.39). They all utilize l-arginine and molecular oxygen as substrates and require the cofactors reduced nicotinamide-adenine-dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydrobiopterin (BH(4)). All NOS bind calmodulin and contain haem. Neuronal NOS (nNOS, NOS I) is constitutively expressed in central and peripheral neurons and some other cell types. Its functions include synaptic plasticity in the central nervous system (CNS), central regulation of blood pressure, smooth muscle relaxation, and vasodila…

medicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumNeovascularization PhysiologicNitric Oxide Synthase Type IIVasodilationNitric Oxide Synthase Type IReviewArginineNitric OxideEndothelial NOSNitric oxideMicechemistry.chemical_compoundEnosInternal medicineRenin–angiotensin systemmedicineAnimalsHumansbiologybusiness.industryCardiovascular AgentsGenetic Therapybiology.organism_classificationBiopterinIsoenzymesNitric oxide synthaseEndocrinologymedicine.anatomical_structurechemistryCardiovascular DiseasescGMP-specific phosphodiesterase type 5biology.proteinEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Evaluation of soluble CD 14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis.

1992

CD14 represents the most specific marker for monocytes/macrophages. It has been demonstrated in vitro that monocytes/macrophages lose this antigen upon activation. Results of studies investigating the expression of membrane-bound CD14 on the surface of monocytes/macrophages in sarcoidosis patients are controversial. To investigate whether the soluble form of CD14 reflects monocyte/macrophage activation in sarcoidosis, serum levels of soluble CD14 were determined concurrently with other serum markers of monocyte/macrophage activation (neopterin, angiotensin-converting enzyme) in 50 consecutive patients with bioptically confirmed sarcoidosis. The patients were allocated to three groups accord…

Lung Diseasesmedicine.medical_specialtySarcoidosisCD14CD4-CD8 RatioLipopolysaccharide ReceptorsAntigens Differentiation MyelomonocyticPeptidyl-Dipeptidase ANeopterinSensitivity and SpecificityMonocyteschemistry.chemical_compoundImmune systemAntigenAntigens CDInternal medicineDrug DiscoverymedicineMacrophageHumansGenetics (clinical)Inflammationmedicine.diagnostic_testMonocyteNeopterinGeneral MedicineMacrophage Activationmedicine.diseaseBiopterinBronchoalveolar lavageEndocrinologymedicine.anatomical_structurechemistrySolubilityImmunologyMolecular MedicineInterleukin-2SarcoidosisBronchoalveolar Lavage FluidBiomarkersThe Clinical investigator
researchProduct